Table 2.
The concentration of carboplatin in plasma by LC-MS (left) and in xenograft tissues and patient PBMCs by ICP-MS (bottom)
| Tissue | Amount of tissue median (RSE) |
Comparison | Method | Subjects (N) | Tissues (N) | Tissues (N) <LOD; <LOQ |
Median conc. (RSE %)a |
P | |
|---|---|---|---|---|---|---|---|---|---|
| b) Carboplatin | Plasma | 50 μL | 0.6 h | LC-MS | 15 | 15 | 0; 0 | 24 (20) | |
| 5 h | 15 | 15 | 15; 15 | <0.01 | |||||
| Carboplatin adducts | TNBC xenograft tissue | 12 μm sections: 1.9 μg DNA (56%) |
All | ICP-MS | 13 | 13 | 0.55 (30%) | ||
| HCC70 | 5 | 5 | 1.85 (42%) | 0.091(Cell source) | |||||
| MDA-MB-231 | 3 | 3 | 0.55 (23%) | ||||||
| MDA-MB-436 | 5 | 5 | 0.54 (27%) | ||||||
| Placebo | 5 | 5 | 0.476 (57) | 0.087 (V yes/no) | |||||
| Veliparib 60mg/kg | 8 | 8 | 0.977 (33) | 0.083(Cell source + V) | |||||
| PBMCs from patients | Derived from 5–15 mL blood, extracted from a median of 2,160,000 cells | 51 | 51 | 0.0552 (30%) | |||||
MALDI matrix-assisted laser desorption/ionization, TBNC triple negative breast cancer, PBMC peripheral blood mononuclear cells, RSE relative standard errors, ROI region of interest, V veliparib
aConcentration (Conc.) of veliparib and carboplatin in mg/L, carboplatin adducts in μmol/g DNA
*P value adjusted for dose